The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This investigation was conducted to evaluate the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS.

Why It Was Studied

Data on the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk of patients with polycystic ovary syndrome (PCOS) were collected.

This randomized, double-blind, placebo-controlled trial was carried out on 60 women with PCOS, aged 18-40 years old.

Who Took Part

The abstract describes 60 women taking part.

PubMed indexes the participants as teenagers, young adults and adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Biomarkers, Blood Glucose, Dietary Supplements, Insulin, Insulin Resistance, Magnesium Oxide and Polycystic Ovary Syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 women.

The publication is from 2019 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.